IPO Price Range: ₹32 - 32
Min Investment
₹1,28,000
IPO Size
₹11 Cr
IPO Status
Quantity in 1 Lot
4000
Max Bid allowed
1
Listing Exchange
NSE
Bid Opening Date | 24 May 2024 |
Bid Closing Date | 28 May 2024 |
Allotment Date | 29 May 2024 |
Issue Size | ₹11.01Cr |
Quantity in 1 lot | 4000 |
Cost effective production and timely fulfilment of orders.
Experienced Promoters and management team.
Well Equipped Manufacturing Facility.
Quality assurance and standards.
Wide range of its products.
Well established relationship with clients.
The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
Any disruptions to the supply, or increases in the pricing, of the raw materials, may adversely affect the supply and pricing of its products and, in turn, adversely affect the companys Business, Cash Flows, Financial Condition and Results of Operations.
Any slowdown or shutdown of its Manufacturing operations at the companys Manufacturing Facilities could have an adverse effect on its Business, Financial Condition and Results of Operations.
Its existing manufacturing facility is concentrated in a single region i.e., Mumbai, Maharashtra and any inability to operate and grow its business in this particular region may have an adverse effect on its business, financial condition, results of operations, cash flows and future business prospects.
The company generates its major portion of sales from its operations in certain geographical regions especially, Gujarat, Dadra & Nagar Haveli and Maharashtra. Any adverse developments affecting its operations in these regions could have an adverse impact on its revenue and results of operations.
The Company is reliant on the demand from the pharmaceutical industry for a significant portion of its revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage the company sales could have an adverse impact on the Companys business and results of operations.
The company does not have long-term agreements with suppliers for its raw materials and any shortfall in the availability or quality of such raw materials could have an adverse effect on its business, financial condition and results of operations.
The company depends on the success of its relationships with the companys customers. Its derives a significant part of its revenue from the companys top 10 customers and the company does not have long term contracts with these customers. If such customers choose not to source their requirements from it, its business, financial condition and results of operations may be adversely affected.
The industry in which the company operates is labour intensive and its manufacturing operations may be materially adversely affected by strikes, work stoppages or increased wage demands by its employees or those of the company suppliers.
The restated financial statements have been provided by peer reviewed chartered accountants who is not statutory auditor of the Company.
Investors | Holdings % |
Sagar Girish Bhanushali | 47.67% |
Mohansinghl Parmar | 52.31% |
Organisation | GSM Foils Ltd |
Headquarters | Thane |
Industry | Non Ferrous Metals |